8VF7 image
Entry Detail
PDB ID:
8VF7
EMDB ID:
Title:
Modifying portion of human FASN with NADPH and the ACP at the ER domain
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-12-21
Release Date:
2025-02-26
Method Details:
Experimental Method:
Resolution:
3.20 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Fatty acid synthase
Chain IDs:A
Chain Length:2553
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Fatty acid synthase
Chain IDs:B
Chain Length:2553
Number of Molecules:1
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
4HH B SER modified residue
Ligand Molecules
Primary Citation
Snapshots of acyl carrier protein shuttling in human fatty acid synthase.
Nature 641 520 528 (2025)
PMID: 39979457 DOI: 10.1038/s41586-025-08587-x

Abstact

The mammalian fatty acid synthase (FASN) enzyme is a dynamic multienzyme that belongs to the megasynthase family. In mammals, a single gene encodes six catalytically active domains and a flexibly tethered acyl carrier protein (ACP) domain that shuttles intermediates between active sites for fatty acid biosynthesis1. FASN is an essential enzyme in mammalian development through the role that fatty acids have in membrane formation, energy storage, cell signalling and protein modifications. Thus, FASN is a promising target for treatment of a large variety of diseases including cancer, metabolic dysfunction-associated fatty liver disease, and viral and parasite infections2,3. The multi-faceted mechanism of FASN and the dynamic nature of the protein, in particular of the ACP, have made it challenging to understand at the molecular level. Here we report cryo-electron microscopy structures of human FASN in a multitude of conformational states with NADPH and NADP+ plus acetoacetyl-CoA present, including structures with the ACP stalled at the dehydratase (DH) and enoyl-reductase (ER) domains. We show that FASN activity in vitro and de novo lipogenesis in cells is inhibited by mutations at the ACP-DH and ACP-ER interfaces. Together, these studies provide new molecular insights into the dynamic nature of FASN and the ACP shuttling mechanism, with implications for developing improved FASN-targeted therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures